Skip to Content

Posts tagged with "Cancer"

  • Cancer

    Novocure’s RF Device Shows Efficacy

    I mentioned Novocure and their unusual therapy for glioblastoma multiforma (GBM) a few months back. They’re using electromagnetic fields, which is normally the sort of thing that makes you back away, because there’s so much snake oil dripping all over that area. And their clinical results in resistant patients were not that impressive … Read More
  • Biological News

    Target Invalidation

    Target validation is a key process in drug discovery, naturally. But it’s worth remembering that target invalidation happens more often, and is also important. The first project I worked on in the drug industry proved pretty conclusively that selective antagonism at the D1 dopamine receptor is not an effective therapy for schizophrenia, des… Read More
  • Cancer

    Bromodomain Ligands and Memory

    Epigenetics has been a hot field the last few years (although not quite hot enough for Roche to buy out their partners in the area, Constellation). One of the things that’s driven a lot of bromodomain-focused research in the field has been the availability of a compound called JQ1, from the Bradner lab at Harvard. Read More
  • Cancer

    Kite and the Rumors

    While we’re on the subject of optimistic news in oncology, Kite Pharma (one of the many players in the chimeric antigen receptor T-cell, CAR-T space) has disclosed some details of its clinical trial in patients with refractory aggressive non-Hodgkin’s lymphoma. That’s just as bad as it sounds – these are people who have fai… Read More
  • Cancer

    ABT-199 Nears Its Finish Line

    A couple of years back, AbbVie ran into an unusual problem in the clinic. Their Bcl ligand, ABT-199, was working a bit too well, and killing off so many leukemia cells that the resulting cellular debris was causing kidney trouble in some patients. The company immediately started working on clinical protocols to get things restarted… Read More
  • Business and Markets

    GlaxoSmithKline’s New Strategy, Defended

    GlaxoSmithKline’s Moncef Slaoui has an interview in the Philadelphia Inquirer, and he’s responding to critics of the company’s strategy (and to rumors about it): Slaoui suggested some reality for pharma cheerleaders: First, most Americans think drug prices are way too high and sooner or later the bottom will fall out from those fi… Read More
  • Business and Markets

    Sanofi Pays to Get Back Into Oncology

    You may recall that Sanofi basically threw its hands up in the air some time back about its entire oncology R&D efforts. Or, since they’re so relentlessly French over there, perhaps it was the Gallic Shrug instead. Either one would fit – the company just wasn’t seeming to get anywhere. So when that happens, what… Read More
  • Cancer

    An Irresponsible Statement About Curing Cancer

    OK, let’s stop doing this. Here’s the head of the Fred Hutchinson Cancer Institute, telling people that “It is actually plausible that in 10 years we will have cures and therapies for most, if not all, human cancers”. I object, on several grounds. (1) Most, if not all? Although some great progress has been made… Read More
  • Aging and Lifespan

    Another Longevity Target

    Add another potential target to the longevity list: this paper in Cell (open access, actually) provides evidence that the well-known Ras-ERK-ETS pathway is also involved in lifespan. This is work in Drosophila, which is one of the usual places to look for this sort of thing. Figure 6 in the paper proposes a way to… Read More
  • Business and Markets

    Bristol-Myers Squibb Sues a Former VP

    You don’t often see noncompete agreements invoked in the biopharma industry, but here’s one. According to Pharmalot, Bristol-Myers Squibb is suing a former executive (David Berman) for taking a job with AstraZeneca. Berman was highly placed in BMS’s immuno-oncology area, and this is such a competitive environment that they feel th… Read More